[Role of interleukin 2 in the pathogenesis and clinical course of multiple sclerosis]

[Article in Polish]

Review

[Article in Polish]

W Cendrowski. Neurol Neurochir Pol. 1986 Mar-Apr.

. 1986 Mar-Apr;20(2):143-6.

No abstract available

Similar articles

Characterization of antigen-specific T cells in multiple sclerosis twins with elevated responses to measles virus.
Greenstein JI, Jacobson S, Richert JR, McFarland HF. Greenstein JI, et al. Ann N Y Acad Sci. 1984;436:511-2. doi: 10.1111/j.1749-6632.1984.tb14834.x. Ann N Y Acad Sci. 1984. PMID: 6085229 No abstract available.
[Characteristics of cellular immunity in multiple sclerosis].
Demina TL, Boĭko AN, Balashov KE, Pinegin BV. Demina TL, et al. Zh Nevropatol Psikhiatr Im S S Korsakova. 1989;89(2):35-41. Zh Nevropatol Psikhiatr Im S S Korsakova. 1989. PMID: 2524943 Russian.
[Drug treatment in multiple sclerosis--1995].
Achiron A. Achiron A. Harefuah. 1995 Dec 15;129(12):579-83. Harefuah. 1995. PMID: 8682363 Review. Hebrew. No abstract available.
Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting.
Stinissen P, Raus J. Stinissen P, et al. Acta Neurol Belg. 1999 Mar;99(1):65-9. Acta Neurol Belg. 1999. PMID: 10218096 Review.
Elevated levels of soluble interleukin-2 receptors in multiple sclerosis.
Greenberg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL. Greenberg SJ, et al. N Engl J Med. 1988 Oct 13;319(15):1019-20. doi: 10.1056/NEJM198810133191517. N Engl J Med. 1988. PMID: 3138540 No abstract available.